A randomized, placebo-controlled, double-blinded Phase III trial of XmAb5871 in IgG4-RD

Trial Profile

A randomized, placebo-controlled, double-blinded Phase III trial of XmAb5871 in IgG4-RD

Planning
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs XmAb 5871 (Primary)
  • Indications Immunological disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Feb 2018 According to a Xencor media release, Engagement with the European Medicines Agency to discuss a path forward for Phase 3 development in IgG4-RD expected in early 2018.
    • 14 Nov 2017 New trial record
    • 07 Nov 2017 According to a Xencor media release, the company met with the Division of Pulmonary, Allergy and Respiratory Products (DPARP) of FDA to discuss this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top